Extract: "While Australia will quickly lay claim to it if researchers do manage develop one, the project has received global support including from Dutch pre-clinical lab Viroclinics Xplore.“Viroclinics Xplore is investigating in more detail the vaccine’s ability to protect from direct challenge by the live virus in multiple animal models, and without this partnership this just wouldn’t have been possible in this time frame with the capabilities we have here in Australia,” joint project leader Keith Chappell said.
It’s also received significant commercial backing in order to keep the project funded and running smoothly. It’s been helped along by the likes of former General Electric life sciences company Cytiva and Australian blood giant and biotech darling CSL among others.
“When you start combining clinical readiness with scale-up manufacturing, the costs quickly escalate and our primary goal here was to try and break down the financial constraints as much as we could,” program director Trent Munro said."
Extracts: "The group recently announced a collaboration with Cytiva to enable key manufacturing activities and discussions are ongoing with other commercial entities."
"“When you start combining clinical readiness with scale-up manufacturing, the costs quickly escalate and our primary goal here was to try and break down the financial constraints as much as we could,” Professor Munro said."
"Other partners include Lonza, Thermo Fisher Scientific, Syneos Health and the CSIRO and the team has also been given access to key adjuvant technology from CSL/Seqirus, Dynavax and GSK."
Part of the broader team ....
CSL Price at posting:
$311.40 Sentiment: Buy Disclosure: Held
(20min delay)